Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Sorrento Valley, San Diego, California. Nuplazid, a drug developed by Acadia in the late 1990s, "was designed to stimulate a subset of the brain’s serotonin receptors, or the proteins that govern memory, cognition and learning." On April 29, 2016, the FDA approved Acadia's drug, Nuplazid, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Nuplazid is the trade name for Acadia's proprietary molecule, pimavanserin, a selective serotonin inverse agonist preferentially targeting 5-HT2a receptors. Acadia had partnered with Biovail in the late-stage clinical testing of the drug, which showed trial failures as of 2009. More information...
According to PR-model, acadia-pharm.com is ranked 711,285th in multilingual Wikipedia, in particular this website is ranked 424,615th in English Wikipedia.
The website is placed before samurai-hiroshi-shop.jp and after hablemosdeinsectos.com in the BestRef global ranking of the most important sources of Wikipedia.
